UCB First Half-Year 2006 Financial Results
Strong revenue growth up 12% to 1.3 billion euro
Net profit from continuing operations up 44% to 237 million euro
and substantial royalty income contribution
performance from Xyzal®
indications for Cimzia(TM), and successors of Keppra®
sale of non-core business (Bioproducts) and products (Delsym®, Corifeo®, Gastrocrom®) after restructuring
Brussels (Belgium), 27 July 2006, 7:00 AM CET - UCB today announced its financial results for the six months ended 30 June 2006.
Roch Doliveux, CEO of UCB, commenting on the first half 2006 performance, said: "UCB performed well in the first half of 2006, delivering solid results financially, in R&D and strategically. Keppra®, now UCB's number one product, achieved outstanding growth and our allergy franchise continued to grow driven by Xyzal® and Zyrtec®. Significant progress was also made in our R&D pipeline, with the launch of a phase III trial for Keppra® XR, the new extended release form of Keppra® and approval of a number of new Keppra® indications. Furthermore Cimzia(TM) was filed for regulatory approval in Crohn's disease with the FDA and European Medicines Agency (EMEA) and achieved extremely encouraging phase II results in psoriasis."
"We are also on track in our preparations for a targeted launch of Cimzia(TM) in Crohn's disease in the first half of 2007. Finally, the NDA for Xyzal® has been filed with the FDA."
Stay up-to-date on the latest news and information from UCB